Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
Download the White Paper "802.11ac in the Enterprise: Technologies and Strategies" to learn from industry expert Craig Mathias about the technologies behind 802.11ac, deployment misconceptions and review steps that every organization should take in getting ready for 802.11ac. Download today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!